Citizens Jmp reissued their market outperform rating on shares of Celcuity (NASDAQ:CELC – Free Report) in a report released on Monday morning,Benzinga reports. Citizens Jmp currently has a $177.00 price objective on the stock.
A number of other research firms have also weighed in on CELC. Wall Street Zen lowered shares of Celcuity from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Citigroup restated a “market outperform” rating on shares of Celcuity in a research report on Monday. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. Stifel Nicolaus cut their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, Needham & Company LLC cut their price target on Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a report on Friday, August 14th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $154.55.
View Our Latest Stock Report on Celcuity
Celcuity Trading Up 0.4%
Celcuity (NASDAQ:CELC – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). Equities research analysts predict that Celcuity will post -4.51 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Celcuity
Large investors have recently bought and sold shares of the stock. California State Teachers Retirement System increased its holdings in shares of Celcuity by 91.2% during the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after buying an additional 12,201 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Celcuity in the fourth quarter valued at $1,058,000. Jennison Associates LLC acquired a new position in Celcuity in the fourth quarter valued at $22,911,000. Geode Capital Management LLC grew its position in Celcuity by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company’s stock valued at $82,872,000 after acquiring an additional 64,213 shares during the period. Finally, TD Asset Management Inc increased its stake in Celcuity by 34.0% during the fourth quarter. TD Asset Management Inc now owns 97,526 shares of the company’s stock worth $9,727,000 after acquiring an additional 24,730 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.
Celcuity Company Profile
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Read More
- Five stocks we like better than Celcuity
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
